ImmuCell plans $3.5M First Defense capacity boost

ImmuCell Corporation outlined a manufacturing capacity expansion focused on its flagship First Defense® product line.

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ImmuCell Corporation outlined a manufacturing capacity expansion focused on its flagship First Defense® product line. The Board authorized a program that shifts resources away from the previously planned in-house Re-Tain® production toward expanded First Defense® output.

The first phase will start immediately, renovating the former Re-Tain® facility and installing a new, higher-capacity freeze dryer. This phase is expected to take about 12 months and cost approximately $3.5 million. A second phase will repurpose additional Re-Tain® equipment and add automation to further expand First Defense® colostrum processing, with the goal of reliably meeting expected customer demand.

Insights

ImmuCell is reallocating capital to expand its core First Defense® capacity.

ImmuCell is pivoting facilities and equipment away from in-house Re-Tain® manufacturing to expand production of its established First Defense® line. The Board approved a manufacturing capacity expansion program, signaling operational focus on meeting anticipated demand for this product family.

The first phase involves a roughly $3.5 million investment over about 12 months to renovate the former Re-Tain® facility and add a higher-capacity, more reliable freeze dryer. A later phase will repurpose Re-Tain® equipment and add automation to expand colostrum processing, though specific costs and timing are not detailed.

The disclosure frames these steps as necessary to stay ahead of current and future demand growth for First Defense®. Execution will depend on completing renovations and engineering work as described, and the company notes typical forward-looking risks that could cause actual outcomes to differ from these plans.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Phase one capex: $3.5 million Phase one duration: 12 months

2 metrics

Phase one capex $3.5 million Estimated cost of first expansion phase

Phase one duration 12 months Expected time to complete initial expansion

Key Terms

Regulation FD Disclosure, manufacturing capacity expansion program, freeze dryer, forward-looking statements

4 terms

Regulation FD Disclosure regulatory

"ITEM 7.01 Regulation FD Disclosure In late December 2025 and early January 2026"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

manufacturing capacity expansion program financial

"ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program"

freeze dryer technical

"adding a new freeze dryer with greater capacity and reliability than the Company's current freeze-drying equipment"

forward-looking statements regulatory

"Forward-Looking Statements. This on contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What manufacturing expansion did ImmuCell (ICCC) approve in June 2026?

ImmuCell approved a manufacturing capacity expansion focused on its First Defense® product line. The plan repurposes facilities and equipment previously intended for Re-Tain® to increase drying and colostrum processing capacity and better meet expected customer demand for First Defense® products.

How much will ImmuCell’s first-phase capacity expansion for First Defense® cost?

The first phase of ImmuCell’s capacity expansion is expected to cost approximately $3.5 million. This spending covers renovating the former Re-Tain® facility and adding a new, higher-capacity freeze dryer to increase and stabilize production of the First Defense® product line.

What is the expected timeline for ImmuCell’s initial expansion phase?

The initial expansion phase is expected to take approximately 12 months. During this period, ImmuCell plans to renovate the former Re-Tain® facility and install a new freeze dryer, aiming to stay ahead of both current and anticipated demand growth for First Defense® products.

How is ImmuCell (ICCC) using former Re-Tain® facilities and equipment?

ImmuCell is converting former Re-Tain® manufacturing facilities and equipment to support First Defense® production. The first phase renovates the Re-Tain® facility for expanded drying, while a second phase will repurpose Re-Tain® equipment and add automation to boost colostrum processing capacity for First Defense®.

Why is ImmuCell expanding capacity for its First Defense® product line?

ImmuCell is expanding First Defense® capacity to better meet expected customer demand. The company describes the investments as intended to strengthen its ability to reliably manufacture First Defense® products, staying ahead of both current requirements and anticipated future demand growth for the line.

What does the second phase of ImmuCell’s expansion program involve?

The second phase will repurpose Re-Tain® equipment and add new equipment and automation to replace and expand First Defense® colostrum processing capacity. It will require additional investments, including detailed engineering work to develop an efficient, scalable production process supporting higher First Defense® volumes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/10/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 4, 2026

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

DE		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 Regulation FD Disclosure

In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equipment for expanded production of the Company’s flagship First Defense® product line. On June 4, 2026, ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program to execute on that strategy.

The first phase, which will start immediately in order to stay ahead of current and future demand growth, expands drying capacity by renovating in the former Re-Tain® facility and adding a new freeze dryer with greater capacity and reliability than the Company's current freeze-drying equipment. This phase is expected to take approximately 12 months and cost approximately $3.5 million.

In a second phase, the Company will repurpose Re-Tain® equipment and add additional equipment and automation to replace and expand its First Defense® colostrum processing capacity. The second phase will involve additional investments, including for detailed engineering work to develop an efficient and scalable process.

The goal of these capacity expansion investments is to further strengthen ImmuCell’s ability to reliably manufacture First Defense® products to meet expected customer demand.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not historical facts and may be identified by words such as “plans,” “expects,” “intends,” “estimates,” “will,” “may,” and similar expressions. Such statements include, without limitation, statements regarding our business plans and strategies, projected financial and operating performance, expected demand for our products (including the First Defense® product line), and the development and commercialization of our products. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied herein. We disclaim any undertaking to update any forward-looking statement, whether as a result of new information, future developments or otherwise.

Item 9.01. Exhibits.

(d) Exhibits.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUCELL CORPORATION

Date: June 10, 2026	By:	/s/ Timothy C. Fiori
		Timothy C. Fiori
		Chief Financial Officer

Exhibit Index

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

ImmuCell plans $3.5M First Defense capacity boost

Rhea-AI Filing Summary

Positive

Negative